EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY

被引：3

作者：

Coates, L. C. ^{[1
]}

Gossec, L. ^{[2
]}

Theander, E. ^{[3
]}

Bergmans, P. ^{[4
]}

Neuhold, M. ^{[5
]}

Karyekar, C. ^{[6
]}

Shawi, M. ^{[6
]}

Noel, W. ^{[5
]}

Schett, G. ^{[7
]}

Mcinnes, I. ^{[8
]}

机构：

[1] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England

[2] Sorbonne Univ, Rheumatol, Paris, France

[3] Janssen Sci Affairs LLC, Immunol, Solna, Sweden

[4] Janssen, Biostat, Breda, Netherlands

[5] Janssen Sci Affairs LLC, Immunol, Brussels, Belgium

[6] Janssen Global Serv LLC, Immunol, Horsham, W Sussex, England

[7] Univ Erlangen Nurnberg, Internal Med 3, Erlangen, Germany

[8] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

来源：

关键词：

DOUBLE-BLIND;

D O I：

10.1136/annrheumdis-2021-eular.42

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0230

引用

页码：140 / 141

页数：2

共 3 条